https___www.marketresearch.co.jp_mrc2106a153-hepatitis-therapeutics-market-growth-trends_.xml
https___shukrabar.nagariknetwork.com_news_194_1.xml
1.1 2.1 3.1 4.1 5.1 5.2 5.3 5.4 6.1 7.1 7.2 7.3 8.1 8.2 8.3 8.4 8.5 8.6 8.7 9.1 10.1 10.2 10.3 11.1 12.1 13.1 14.1 15.1 15.2 15.3 16.1 16.2 16.3 17.1 17.2 17.3 18.1 19.1 19.2 19.3 20.1 21.1 21.2 21.3 21.4 21.5 22.1 22.2 22.3 23.1 23.2 24.1 25.1 25.2 25.3 26.1 27.1 28.1 29.1 30.1 31.1 32.1 33.1 34.1 35.1 36.1 37.1 38.1 39.1 40.1 41.1 42.1 43.1 44.1 45.1 46.1 47.1 48.1 49.1 50.1 51.1 52.1 53.1 54.1 55.1 56.1 57.1 58.1 59.1 60.1 61.1 62.1 63.1 64.1 65.1 66.1 69.1 71.1 75.1 76.1 80.1 81.1 82.1 83.1 85.1 86.1 87.1 89.1 90.1 91.1 92.1 93.1 94.1 95.1 96.1 97.1 98.1 99.1 100.1 101.1 102.1 103.1 105.1
• 販売価格(消費税別)• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください. • お支払方法:銀行振込(納品後,ご請求書送付) レポート概要 The hepatitis therapeutics market is projected to register a CAGR of 3.5% during the forecast period. COVID‐19’s impact on healthcare resources has adversely affected the delivery of care and outcomes of patients with chronic disease. Therefore, there has been a decrease in the treatment, diagnosis, and follow-up of patients with liver disease and hepatitis, which had negative consequences in the overall healthcare industry. Also, the clinical trials of drugs have been slow down as most of the companies have delayed the start for most of the new studies in several countries. In addition, the COVID-19 pandemic has observed a decrease in outpatient services by patients with chronic hepatitis which further highly impacted the overall market growth. The market will show rapid growth due to the increasing prevalence of viral hepatitis, favorable government support for creating awareness about hepatitis, and increasing availability of technologically advanced therapeutic products. Hepatitis is an inflammation, or swelling, of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver, which can be fatal. Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-colored bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exam, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer. According to the World Health Organization (WHO) 2020, globally, 325 million people are estimated to be infected with hepatitis B or C. In addition, According to WHO, in 2019, Hepatitis B prevalence is highest in the WHO Western Pacific region and the WHO African region, where 6.2% and 6.1% of the adult population is infected respectively. Moreover, in Europe Hepatitis B and C affect millions of people. According to the World health Organization 2019, Hepatitis B is an infectious disease which has affected around 15 million population in WHO European Region. In addition to the same source Hepatitis C which is a liver disease had affected around 14 million in the European region. Furthermore, according to the U.S. Department of Health & Human Services, in 2018, most adults in their 20s and 30s made up 36.5% of newly reported chronic hepatitis C infections in the United States and this is expected to increase in the forecast period. An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the hepatitis therapeutics market. Key Market Trends Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market Since the COVID-19 outbreak, the market has been negatively impacted due to the supply chain and market disruption, and by its financial impact on firms and financial markets. The pandemic has negatively impacted the pharmaceutical industry in terms of the supply and demand for different drugs. Similarly, it is also expected to impact the overall growth of the global hepatitis market. Hepatitis C is a liver infection which is caused by the hepatitis C virus. Hepatitis C can range from a mild to serious and lifelong illness. Acute hepatitis C occurs within the first 6 months after individual is exposed to the hepatitis C virus and chronic hepatitis C can be a lifelong infection with the hepatitis C virus if left untreated. According to World Health Organization (WHO) 2020, hepatitis C virus (HCV) infection affects over 71 million people globally. According to the same source, the hepatitis C virus is a bloodborne virus and the common mode of infection is through exposure to small quantities of blood. This usually happens with unsafe injection practices and unsafe health care. Hepatitis C segment holds a significant market share in the hepatitis therapeutics market and is anticipated to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions and the growing availability of effective drug regimens in the market. Moreover, several product launches by the major players are also boosting the segment growth. For example in 2019 the U.S. Food and Drug Administration approved Mavyret (glecaprevir and pibrentasvir) tablets for the treatment of six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. In additon in 2018 the company Natco Pharma had launched fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C in India North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period The COVID-19 pandemic highlighted the need for North American companies and research organizations to collaborate with the government to develop new drugs, in order to meet future health crisis. In addition, the United States is the most COVID-affected country across the world. The supply chain of products was highly impacted in this country. Initially, the decline in diagnostic and therapeutic procedures has affected the market growth. However, as the restrictions ease, the demand for hepatitis therapeutic will significantly rise and thus drives the overall market growth in the forecasted period. North America expected to hold a major market share in the hepatitis therapeutics market due to an increase in the incidence of hepatitis, mortality due to hepatitis, and increased spending on drugs for the treatment of hepatitis in this region. According to the Center for Disease Control (CDC) 2018, estimates about 2.4 million people are living with hepatitis C in the United States, and approximately 850,000 people in this region estimated to be living with hepatitis B. In addition to the same source, 67% of persons infected with hepatitis B virus do not know they have the virus. Furthermore, favorable reimbursement policies, high adoption rates of advance therapeutics and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent. Furthermore, presence of the key market players coupled with growing awareness programs, recent products launch in the region are anticipated to boost the growth of the market in the United States. For instance, in December 2019, a new strategic plan was initiated in the United States by the National Institutes of Health outlines to intensify ongoing HBV research with the goals of developing a cure and improving scientific understanding of the virus while creating improved strategies for screening and treating patients. Competitive Landscape The Hepatitis Therapeutics Market is fragmented competitive and consists of several major players. However, in terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited and Cipla, Inc. Reasons to Purchase this report: – The market estimate (ME) sheet in Excel format – 3 months of analyst support 1 INTRODUCTION 1.1 Study Assumptions and Market Definition 1.2 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Prevalence of Viral Hepatitis 4.2.2 Favorable Government Support for Creating Awareness about Hepatitis 4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products 4.3 Market Restraints 4.3.1 Stringent Regulatory Issues 4.3.2 Poor Reimbursement Policies 4.4 Porter’s Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry 5 MARKET SEGMENTATION 5.1 By Disease Type 5.1.1 Hepatitis A 5.1.2 Hepatitis B 5.1.3 Hepatitis C 5.1.4 Hepatitis D 5.1.5 Other Types 5.2 By Drug Class 5.2.1 Interferon 5.2.2 Monoclonal Antibody 5.2.3 Non-structural protein 5A (NS5A) inhibitors 5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors 5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors 5.2.6 Multi Class Combination 5.2.7 Others 5.3 Geography 5.3.1 North America 5.3.1.1 United States 5.3.2 Europe 5.3.2.2 United Kingdom 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.4 Australia 5.3.3.5 South Korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East and Africa 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East and Africa 5.3.5 South America 5.3.5.2 Argentina 5.3.5.3 Rest of South America 6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Merck & Co., Inc 6.1.2 Gilead Sciences, Inc 6.1.3 AbbVie Inc 6.1.4 Bristol Myers Squibb Company 6.1.5 F. Hoffmann-La Roche, Ltd 6.1.6 LAURUS Labs 6.1.7 Zydus Cadila 6.1.8 Hetero Healthcare Limited 6.1.9 NATCO Pharma Limited 6.1.10 Cipla, Inc 6.1.11 Johnson & Johnson 7 MARKET OPPORTUNITIES AND FUTURE TRENDS
1.1 2.1 3.1 4.1 5.1 6.1 7.1 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 18.1
डा. दिलिप शर्मा कलेजो रोग विशेषज्ञ, वीर अस्पताल मानव शरीरका महŒवपूर्ण अंगमध्ये कलेजो पनि एक हो । कलेजोमा ‘हेपाटोट्रोपिक भाइरस’ का कारण हुने संक्रमणलाई भाइरल हेपाटाइटिस भनिन्छ । कलेजोलाई दुई प्रकारको भाइरसले असर गर्छ । एउटा ‘हेपाटोट्रोपिक’ र अर्को ‘नन–हेपाटोट्रोपिक’ । हेपाटोट्रोपिक भाइरसअन्तर्गत हेपाटाइटिस ‘ए, बी, सी, डी र ई’ पर्दछन् । यसले कलेजोलाई मात्र असर गरे पनि शरीरका अन्य भागमा दीर्घकालीन असर पु¥याउँदैनन् । नन–हेपाटोट्रोपिक भाइरसअन्तर्गत ‘हर्पिस सिम्लेक’ र ‘इब्स्टेनवार’ भाइरस पर्दछन् । यिनले भने कलेजोका साथै शरीरका अन्य भागलाई पनि असर पु¥याउँछन् । भाइरल हेपाटाइटिस ए, बी, सी, डी र ईलाई दुई समूहमा बाँडिएको हुन्छ । पहिलो समूहमा ‘ए र ई’ पर्छन् । यो विशेष गरी प्रदूषित पानी तथा खानेकुराबाट सर्छ । यसले तुरून्त असर गरे पनि दीर्घकालीन असर भने गर्दैन । अर्को समूहमा बी, सी र डी पर्छन्् । यो रगत, रगतजन्य पदार्थ, सिरिन्ज, शारीरिक तरल पदार्थ वा आमाबाट बच्चामा सर्छ । यो दीर्घकालीन प्रकृतिको पनि हुन्छ र कलेजोलाई असरसमेत गर्छ । हेपाटाइटिस बी एचआईभी÷एड्सभन्दा पनि खतरनाक भनेर प्रचार गरिए पनि शरीरको प्रतिरोधात्मक क्षमताका कारण ९० प्रतिशत वयस्क मानिसमा छ महिनाभित्र आफँै निको भएर जान्छ । बाँकी १० प्रतिशतमा यसले नरम कलेजोलाई कडा पार्दै लान्छ । जसलाई ‘लिभर सिरोसिस’ भनिन्छ । लिभर सिरोसिस भएर पछि क्यान्सर हुने सम्भावना हुन्छ । हेपाटाइटिस भयो भने जन्डिस देखिन्छ । यस्तो हुँदा मुख बार्ने, जडिबुटीको प्रयोग गर्ने, नाइटोमा लेप लगाउने जस्ता काम गरिन्छ । तर, मुख बार्दा पोषणको कमी हुन्छ । जसका कारण रोगसँग लड्ने क्षमतामा ह्रास आउन सक्छ । सरकारले जनचेतनामूलक कार्यक्रममार्फत खानाप्रतिको धारणाबारे आम समुदायलाई स्पष्ट पार्नु जरूरी छ । जन्डिस रोग होइन । यो रोगको लक्षण मात्र हो । उपचार गरेर त्यसको निदान गर्नुपर्छ । यसबारे हामीले न बिरामीलाई राम्ररी बुझाउन सकेका छौँ, न त उनीहरूका परिवारलाई । यसतर्फ ध्यान दिन जरूरी छ । हेपाटाइटिसबाट हरेक वर्ष संसारभर १५ लाख व्यक्तिको मृत्यु हुने गरेको छ । यो संख्या एचआईभी÷एड्सबाट हुने मृत्यु बराबर छ । एचआईभी÷एड्सलाई सरकारी तथा गैरसरकारी संस्था, अन्तर्राष्ट्रिय दातृ संस्थाहरूले जति महŒव दिएका छन्, त्यति हेपाटाइटिसलाई महŒव दिएको पाइँदैन । संसारमा ‘मेडिकल डिजिज’ मा मानिसको ज्यान लिने रोगमध्ये आठौँ ठूलो रोग भाइरल हेपाटाइटिसलाई नेपालमा खासै महŒव दिएको पाइँदैन । अविकसित राष्ट्रमा मात्र होइन विकसितमा पनि यसलाई महŒव कम दिएको पाइन्छ । सरकारले हेपाटाइटिसलाई जनस्वास्थ्य कार्यक्रममा राखेर ग्रामीण स्वास्थ्य चौकीदेखि चिकित्सकसम्म तथा जनस्वास्थ्यसँग चासो राख्ने हरेक व्यक्तिलाई यसको रोकथाम, सर्ने माध्यम तथा उपचारबारे ज्ञान दिन जरूरी छ । आठौँ ठूलो रोग भए पनि मानिसले धेरै चासो नदेखाएका कारण विश्व स्वास्थ्य संगठनले संसारको हेपाटाइटिसप्रतिको धारणा बदल्न र यस रोगबाट पर्ने आर्थिक भारको चेतना जगाउन विश्व हेपाटाइटिस दिवस मनाउन सुरु गरेको छ । हरेक वर्षको जुलाई २८ का दिन हेपाटाइटिस दिवस मनाउने गरिन्छ । यस पटकको हेपाटाइटिस दिवस ‘हेपाटाइटिसको बारेमा पुनर्विचार गरौँ’ भन्ने नाराका साथ मनाइयो । त्यसैले जनचेतनामार्फत हेपाटाइटिस भइसकेका व्यक्तिले कसरी सावधानी अपनाउने र नभएकाले कसरी यसविरूद्ध खोप लगाउने भन्ने बारे बुझाउनुपर्छ । अहिले पनि धेरै व्यक्तिमा हेपाटाइटिसबारे चेतनाको अभाव छ । हेपाटाइटिसका कारण लिभर सिरोसिस तथा लिभर क्यान्सर हुन्छ भन्ने कुरा कतिपयलाई थाहा छैन । लिभर क्यान्सर दोस्रो ठूलो डरलाग्दो क्यान्सर हो । हेपाटाइटिसको रोकथाम गर्न सके ठूलो जनधनको क्षति हुनबाट बचाउन सकिन्छ । सबै हेपाटाइटिसको खोप उपलब्ध छैन । हेपाइटिस ए र बी को मात्र खोप उपलब्ध छ । हेपाटाइटिस बी को खोप लगाउन सकेमा दीर्घकालमा हुने क्षतिबाट बचाउन सकिन्छ । केही व्यक्तिमा हेपाटाइटिस एचआईभी÷एड्सभन्दा पनि डरलाग्दो रोग हो भन्ने भ्रम छ । त्यसैले यसलाई लुकाउने गरिन्छ । तर, यो रोग लाग्दैमा हात मिलाउन नहुने, सँगै बस्न नहुने, एउटै ओछ्यान प्रयोग गर्न नहुने भन्ने होइन । हेपाटाइटिसको भाइरस धेरै समयसम्म बाँच्ने हुनाले डरलाग्दो भनिएको हो । हेपाटाइटिसले कलेजोलाई मात्र असर गर्छ । समस्या देखिइसकेपछि यसलाई लुकाउनुभन्दा पनि समाधानतिर लाग्नुपर्छ । हेपाटाइटिसलाई निको पार्न पनि सकिन्छ । विश्वमा हेपाटाइटिसलाई महŒव नदिइरहेको अवस्थामा नेपालमा पनि सरकार हेपाटाइटिस बी र सी को जोखिमप्रति निकै उदास देखिन्छ । कलेजोका दीर्घ रोगीहरू दिनहुँ वृद्धि भइरहेको आजको समयमा स्वास्थ्य मन्त्रालयले जनस्वास्थ्य कार्यक्रममा हेपाटाइटिस बी र सीप्रति चेतना अभियान चलाउनुपर्ने अवस्था आएको छ । जनचेतनाको कमी भएका कतिपय ठाउँमा मानिसहरू हेपाटाइटिस भएका बिरामीलाई छुन रुचाउँदैनन् । तर, हेपाटाइटिस छोएर सर्ने रोग होइन । आम मानिसमा हेपाटाइटिस कसरी सर्छ भन्ने नै थाहा छैन । विशेष गरी, यो रगत तथा शरीरको तरल पदार्थबाट सर्ने गर्छ । हेपाटाइटिस बी र सी लाग्यो भने पछि गएर उपचार महँगो पर्छ । यो हेपाटाइटिस बीको औषधि दुई वर्ष या जीवनभर पनि सेवन गर्नुपर्ने हुन सक्छ । जसका कारण आर्थिक अवस्था कमजोर भएका व्यक्तिलाई यसको खर्च धान्न मुश्किल पर्न सक्छ । हेपाटाइटिसमा ‘टेनोफोविर’ नामक औषधिको प्रयोग हुन्छ । यो औषधि एचआईभी÷एड्सका बिरामीमा पनि प्रयोग हुन्छ । टेनोफोविर एचआईभीका बिरामीलाई सरकारले निःशुल्क प्रदान गर्दै आएको छ । जबकि, एचआईभीसँगै बराबर मृत्यु हुने हेपाटाइटिसमा सरकारले चासो दिएको छैन । हेपाटाइटिस बी मा न्यून आय भएका बिरामीलाई पनि टेनोफोविर निःशुल्क दिइँदैन । त्यसकारण नेपाल सरकारले हेपाटाइटिस बी भएर उपचार गर्न नसक्ने व्यक्तिलाई भविष्यमा लिभर सिरोसिस र क्यान्सर हुनबाट बचाउन निःशुल्क टेनोफोविर उपलब्ध गराउनुपर्छ । नेपालमा हेपाटाइटिस बी र सीका बिरामी कति छन् भन्ने यकिन तथ्यांक छैन । करिब २ प्रतिशत अर्थात् छ लाखको हाराहारीमा हेपाटाइटिस बी र एक लाख हेपाटाइटिस सीका बिरामी भएको अनुमान छ । तर, सरकारको तथ्यांकमा ५८ हजार मात्र बिरामी देखिएका छन् । यो तथ्यांक पुरानो भएकाले सरकारले नयाँ सर्भे गरेर हेपाटाइटिस बीका बिरामी संख्या तथा हेपाटाइटिस बीले गर्दा लिभर सिरोसिस र क्यान्सर भएका बिरामीको तथ्यांक राख्नुपर्छ । यदि हेपाटाइटिस बी भयो भने टेनोफोविर औषधिको सेवनमा महिनामा तीन हजार खर्च हुन्छ । यदि लिभर क्यान्सर भयो भने सरकारले उपचारका लागि एक लाख रूपैयाँ दिने गरेको छ । तर, हेपाटाइटिस बीको अवस्थामा उसलाई टेनोफोविर निःशुल्क दिन सकिए उसको जीवनको गुणस्तर पनि राम्रो हुने र क्यान्सरविनाको जीवन जिउन सक्छ । सबै बिरामीलाई सरकारले टेनोफोविर निःशुल्क उपलब्ध गराउन सक्दैन भने न्यून आय भएका बिरामीको पहिचान गरी सुविधा दिनुपर्छ । हेपाटाइटिस भएका बिरामीलाई स्वास्थ्यकर्मीले पनि त्यति चासोका साथ नहेर्ने भएकाले स्वास्थ्यकर्मीको पनि धारणा परिवर्तन गर्नुपर्छ । समाजमा यस रोगलाई नकारात्मक रूपमा लिने गरिन्छ । त्यसैले सरकारले अभियान नै चलाएर हेपाटाइटिसबारे जनचेतना फैलाउनु नितान्त आवश्यक छ ।